Waisman JR - Search Results

1

Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.

Bacon ER, Ihle K, Guo W, Egelston CA, Simons DL, Wei C, Tumyan L, Schmolze D, Lee PP, Waisman JR. Bacon ER, et al. Among authors: waisman jr. NPJ Precis Oncol. 2024 Mar 29;8(1):81. doi: 10.1038/s41698-024-00572-3. NPJ Precis Oncol. 2024. PMID: 38553598 Free PMC article.

2

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.

Yuan Y, Yost SE, Cui Y, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Waisman J, Patel N, Vora L, Tumyan L, Bozoghlanian M, Stewart D, Frankel PH. Yuan Y, et al. Oncologist. 2023 Jul 5;28(7):e498-e507. doi: 10.1093/oncolo/oyad026. Oncologist. 2023. PMID: 37023705 Free PMC article. Clinical Trial.

3

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.

Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: waisman jr. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.

4

PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer.

Wang L, Guo W, Guo Z, Yu J, Tan J, Simons DL, Hu K, Liu X, Zhou Q, Zheng Y, Colt EA, Yim J, Waisman J, Lee PP. Wang L, et al. Cell Rep Med. 2024 Feb 20;5(2):101420. doi: 10.1016/j.xcrm.2024.101420. Cell Rep Med. 2024. PMID: 38382468 Free PMC article.

5

Organ-Specific Immune Setpoints Underlie Divergent Immune Profiles across Metastatic Sites in Breast Cancer.

Egelston CA, Guo W, Simons DL, Ye J, Avalos C, Solomon ST, Nwangwu M, Nelson MS, Tan J, Bacon ER, Ihle K, Schmolze D, Tumyan L, Waisman JR, Lee PP. Egelston CA, et al. Among authors: waisman jr. Cancer Immunol Res. 2024 Nov 4;12(11):1559-1573. doi: 10.1158/2326-6066.CIR-23-0718. Cancer Immunol Res. 2024. PMID: 39051632

6

Tumor draining lymph nodes connected to cold triple-negative breast cancers are characterized by Th2-associated microenvironment.

Guo W, Tan J, Wang L, Egelston CA, Simons DL, Ochoa A, Lim MH, Wang L, Solomon S, Waisman J, Wei CH, Hoffmann C, Song J, Schmolze D, Lee PP. Guo W, et al. Nat Commun. 2024 Oct 4;15(1):8592. doi: 10.1038/s41467-024-52577-y. Nat Commun. 2024. PMID: 39366933 Free PMC article.

7

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.

Ge X, Behrendt CE, Yost SE, Patel N, Samoa R, Stewart D, Sedrak M, Lavasani S, Waisman J, Yuan Y, Mortimer J. Ge X, et al. Oncologist. 2023 Jul 5;28(7):e488-e492. doi: 10.1093/oncolo/oyad024. Oncologist. 2023. PMID: 36943382 Free PMC article.

8

HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia.

Rainone M, Behrendt CE, Kasparian S, Nguyen T, Sedrak MS, Lavasani S, Stewart DB, Yuan Y, Mortimer JE, Waisman JR, Patel N, Pullarkat V. Rainone M, et al. Among authors: waisman jr. Breast Cancer. 2023 Sep;30(5):796-801. doi: 10.1007/s12282-023-01473-2. Epub 2023 Jun 16. Breast Cancer. 2023. PMID: 37326930 Free PMC article.

9

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Jhaveri K, et al. Ann Oncol. 2023 Oct;34(10):885-898. doi: 10.1016/j.annonc.2023.08.003. Epub 2023 Aug 18. Ann Oncol. 2023. PMID: 37597578 Free PMC article. Clinical Trial.

10

UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.

Wong MH, Jones VC, Yu W, Bosserman LD, Lavasani SM, Patel N, Sedrak MS, Stewart DB, Waisman JR, Yuan Y, Mortimer JE. Wong MH, et al. Among authors: waisman jr. Cancer Med. 2024 Aug;13(16):e70096. doi: 10.1002/cam4.70096. Cancer Med. 2024. PMID: 39157928 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters